All In Biotech

Drug Trial Radar · NCT06103864

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 625 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

625

Planned (sponsor's estimate)

Start

Nov 23, 2023

Primary completion

Jul 28, 2027

Study completion Sep 30, 2030

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Oct 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.

Conditions

  • Breast Cancer

Interventions

  • Dato-DXdDrug

    Provided in 100mg vials. IV infusion. Experimental drug.

  • DurvalumabDrug

    Provided in 500mg vials. IV infusion. Experimental drug.

  • PaclitaxelDrug

    IV infusion. Active comparator.

  • Nab-paclitaxelDrug

    IV infusion. Active comparator.

  • GemcitabineDrug

    IV infusion. Active comparator.

  • CarboplatinDrug

    IV infusion. Active comparator.

  • PembrolizumabDrug

    IV infusion. Active comparator.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: From randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause (anticipated to be up to 33 months).

Locations

318 sites in 24 countries. Site status is shown where the registry gives one.

  • Research Site

    Daphne, Alabama · Recruiting

  • Research Site

    Springdale, Arkansas · Recruiting

  • Research Site

    Duarte, California · Withdrawn

  • Research Site

    Fountain Valley, California · Recruiting

  • Research Site

    Glendale, California · Recruiting

  • Research Site

    Sacramento, California · Recruiting

  • Research Site

    Santa Rosa, California · Withdrawn

  • Research Site

    Aurora, Colorado · Recruiting

  • Research Site

    Denver, Colorado · Not yet recruiting

  • Research Site

    New Haven, Connecticut · Recruiting

  • Research Site

    Altamonte Springs, Florida · Not yet recruiting

  • Research Site

    Jacksonville, Florida · Withdrawn

  • Research Site

    Miami, Florida · Recruiting

  • Research Site

    Palm Bay, Florida · Withdrawn

  • Research Site

    Plantation, Florida · Recruiting

  • Research Site

    Atlanta, Georgia · Suspended

  • Research Site

    Honolulu, Hawaii · Withdrawn

  • Research Site

    Chicago, Illinois · Recruiting

  • Research Site

    Decatur, Illinois · Withdrawn

  • Research Site

    Elmhurst, Illinois · Withdrawn

  • Research Site

    Naperville, Illinois · Withdrawn

  • Research Site

    New Albany, Indiana · Withdrawn

  • Research Site

    Des Moines, Iowa · Recruiting

  • Research Site

    Lexington, Kentucky · Withdrawn

  • Research Site

    Louisville, Kentucky · Withdrawn

  • Research Site

    Louisville, Kentucky · Withdrawn

  • Research Site

    Baton Rouge, Louisiana · Withdrawn

  • Research Site

    Baton Rouge, Louisiana · Recruiting

  • Research Site

    Baltimore, Maryland · Withdrawn

  • Research Site

    Columbia, Maryland · Recruiting

  • Research Site

    Boston, Massachusetts · Withdrawn

  • Research Site

    Worcester, Massachusetts · Withdrawn

  • Research Site

    Detroit, Michigan · Recruiting

  • Research Site

    Grand Rapids, Michigan · Withdrawn

  • Research Site

    Saint Paul, Minnesota · Recruiting

  • Research Site

    Hattiesburg, Mississippi · Withdrawn

  • Research Site

    St Louis, Missouri · Recruiting

  • Research Site

    Albuquerque, New Mexico · Recruiting

  • Research Site

    Albany, New York · Withdrawn

  • Research Site

    New York, New York · Recruiting

Showing 40 of 318 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.